Search Results - Michael Chisamore

782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial updat... by Paolo A Ascierto, Georgina V Long, Michael Chisamore, Paola Queirolo, Adnan Khattak, Anders Jespersen, Daniela Kleine-Kohlbrecher, Nadia Viborg, Mads Lausen, Stine F Thorsen, Thomas Trolle

753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors by Costantine Albany, Andrea Pirzkall, Michael Chisamore, Jennifer Visich, Elizabeth I Buchbinder, Xiaohan Liu, David R Spigel, Kelly D Moynihan, Christopher DelNagro, Matt Axt, Mark Sayles

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitor... by Alexander Stevenson, Jianjun Gao, Pavlos Msaouel, Nizar Tannir, Mehmet Altan, Shi-Ming Tu, Michael Chisamore, Matthew Campbell, George Blumenschein, Xiuning Le, Frank Mott, Amishi Shah, Jordi Rodon, Imke Mulder

598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NC... by Michael Chisamore, Noelly Madeleine, Austin Rayford, Gro Gausdal, David R Micklem, Magnus Blø, Dina Alzhanova, Josephine Amalia Taverna, Chia-Nung Hung, Rolf A Brekken, Claudia Gorcea-Carson, Cristina Oliva, Nigel McCracken

704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer by Qingfeng Zhu, Robert Anders, Damian Trujillo, Dirk G Brockstedt, Michael Chisamore, Juraj Adamik, Paul D Kassner, William Ho, Rakesh Kumar Goyal, Adam Grant, Shoji Ikeda, Marvin Au, Denise Nagata, Eugene Lurie, Mohsen Sabouri Ghomi

Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice by Stacy K. Thomas, Max M. Wattenberg, Shaanti Choi-Bose, Mark Uhlik, Ben Harrison, Heather Coho, Christopher R. Cassella, Meredith L. Stone, Dhruv Patel, Kelly Markowitz, Devora Delman, Michael Chisamore, Jeremy Drees, Nandita Bose, Gregory L. Beatty

Get full text

629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoin... by Jameel Muzaffar, Tae Min Kim, Julie Brahmer, Dirk G Brockstedt, Chia-Chi Lin, Michael Chisamore, Ki Hyeong Lee, Paul D Kassner, Nuttapong Ngamphaiboon, William Ho, Nicole Nasrah, Pratibha Desai, Yin-Hsun Feng, Shang-Yin Wu, Rakesh Kumar Goyal

757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab by Michael Chisamore, Jeffrey Yachnin, Ana Carneiro, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Lars Ny, Zsuzsanna Pápai, Kristoffer Staahl Rohrberg, Kirstie Cleary, Jan Anders Nilsson, Sean Lim, Johan E Wallin, Istvan Lang, Harriet Walter, Rikke H Lovendahl Eefsen, Edvard Abel, Robert Oldham, Susanne Gertsson